Explore cutting-edge pancreatic cancer research with Novotech CRO's disease report. Learn about new treatments, clinical trials, and future innovations in pancreatic cancer care.
Pancreatic cancer is one of the most fatal gastrointestinal cancers, ranking sixth in cancer-related deaths worldwide. Pancreatic cancer is more frequent in elderly patients, with higher incidences in males than females. According to GLOBOCAN 2022, there were significantly more new pancreatic cancer cases in men than in women. The prognosis for pancreatic cancer is poor, with a five-year survival rate of 2%-10%. Risk factors include age, gender, and lifestyle choices. Globally, pancreatic cancer poses a significant health burden with over 500,000 new cases reported in 2022. Asia recorded the highest incidence, followed by Europe, North America, and the rest of the world regions. These diverse trends reflect the complex epidemiological landscape of pancreatic cancer across the world.
The NCCN, ESMO, and Japan Pancreas society guidelines for 2024 provide detailed recommendations for pancreatic cancer treatment across various stages. They emphasize the use of FOLFIRINOX and gemcitabine-based therapies for different stages, with specific regimens for patients based on their diagnosis, cancer stage, and genetic mutations. These guidelines highlight the importance of tailored treatment strategies to improve survival rates for pancreatic cancer patients, including women and those with new cases, by leveraging clinical data and statistics.
Since 2019, the biotech and biopharma industry initiated over 2,000 pancreatic cancer trials. North America led in the number of trials conducted, followed by Asia-Pacific and Europe, while the rest of the world contributed moderately. The United States is prominent in North America, while Mainland China leads in the Asia-Pacific region. Significant research efforts are also observed in Spain within Europe and in Israel across the rest of the world. In terms of patient recruitment trends, Asia-Pacific shows shorter recruitment durations and faster patient recruitment rates.
Shifting focus to the marketed and drug pipeline trends, there are diverse products offered by companies like Astellas Pharma Inc., Bristol Myers Squibb Co., and Sun Pharma Advanced Research Company Ltd., covering small molecule, peptide, and drug/device combinations. Multiple ongoing phase III trials also demonstrate continued efforts in developing these and other innovative drug modalities such as the antibody, small molecule, and protein. These research and development initiatives reflect the companies' comprehensive efforts to address pancreatic cancer treatment complexities and improve patient outcomes
To conclude, pancreatic cancer research has advanced considerably, offering renewed hope to patients and their families. Progress in neoadjuvant chemotherapy, RAS-targeted therapies, and stroma-modifying drugs is leading to better outcomes, while new chemotherapy combinations like NALIRIFOX are receiving approval. The outlook for pancreatic cancer treatment is encouraging, with personalized medicine, early detection, and targeted biological therapies emerging as significant breakthroughs. A holistic approach that combines surgery, chemotherapy, radiation, and innovative therapies is expected to further improve survival rates and enhance patient quality of life.
Novotech, a global clinical CRO, has partnered with numerous biotech companies and completed hundreds of oncology projects, including those in immuno-oncology and advanced therapies for indications such as pancreatic cancer. Novotech supports over 5,000 clinical projects across all phases and bioequivalence studies. Recognized for its contributions, Novotech has received the CRO leadership award 2023 and has been the Asia-Pacific CRO company of the year since 2006.
Discover more about the global clinical trial landscape for pancreatic cancer by downloading our comprehensive disease report.